Evolus, Inc.

EOLS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Operating Activities
Net Income $-8.1M $-10.7M $130.0K $-15.7M $-17.1M $-18.9M $-6.8M $-19.2M
Depreciation & Amortization $1.5M $2.3M $3.9M $1.1M $932.0K $1.6M $1.4M $1.1M
Depreciation $461.0K $453.0K $431.0K $271.0K $244.0K $287.0K $387.0K $283.0K
Amortization $1.9M $1.9M $1.8M $1.7M $1.5M $1.3M $989.0K $803.0K
Stock-Based Compensation $5.6M $5.1M $5.1M $5.1M $4.5M $5.9M $6.2M $5.2M
Net Cash from Operating Activities $-3.6M $-10.0M $12.8M $-14.7M $-24.8M $-15.6M $4.8M $-5.7M
Investing Activities
Capital Expenditures $50.0K $415.0K $1.5M $955.0K $688.0K $319.0K $438.0K $313.0K
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-500.0K $-1.7M $-2.2M $-2.2M $-2.3M $-1.9M $-1.4M $-1.4M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $-365.0K $7.6M $77.0K $-1.8M $20.7M $-1.6M $-1.3M $-1.4M
Net Change in Cash $-4.6M $-4.0M $10.3M $-18.2M $-6.2M $-19.1M $1.9M $-8.6M
Free Cash Flow $-3.6M $-10.4M $11.3M $-15.6M $-25.5M $-16.0M $4.4M $-6.0M
← Newer Page 1 of 5 Older →